As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
MDMA-assisted therapy (MDMA-AT) shows promise in treating PTSD and comorbid eating disorders. A study found significant reductions in eating disorder symptoms with MDMA-AT compared to placebo in severe PTSD patients.
Adele LaFrance, Timothy Brewerton
Dr. Zeifman, Dr. Traynor, and Dr. Roberts explore the potential of psychedelic-assisted psychotherapy for Borderline Personality Disorder, discussing observational studies, promising research, and upcoming clinical trials in this symposium.
Daniel E Roberts, Jenna Traynor, Richard Zeifman
Resurgence in psychedelic assisted psychotherapy (PAP) shows promise in treating mental illnesses, integrating psilocybin with Psychohistoriographic Brief Therapy (PBT) in a structured treatment protocol. Caribbean programs must prioritize safety and
Winston De La Haye
Dr. Dölen presents evidence linking psychedelics to reopening the social reward learning critical period, suggesting a shared mechanism across these drugs. This metaplastic restoration of oxytocin-mediated long-term depression may have
Depression remains a major unmet medical need globally, with current medications often providing inadequate relief and leading to high costs. Psychedelic therapies, like psilocybin, show promise in revolutionizing mental health
Charles Raison
Dr. Anne Wagner and Dr. Michael Mithoefer discuss therapeutic potential of MDMA for couples, sharing insights from their MDMA-assisted couples therapy trials and ongoing research with Dr. Chandra Khalifian and
Chandra Khalifian, Leslie Morland, Kayla Knopp
NIMH Director Joshua A. Gordon and trauma researcher Barbara O. Rothbaum discuss the current state and future directions of psychedelic research, emphasizing the need for deeper understanding and robust study
Joshua A Gordon
Dr. Barbara Rothbaum discusses combining MDMA with prolonged exposure therapy for PTSD, citing theoretical and translational research supporting a synergistic mechanism of action for treatment.
Barbara Rothbaum, Lynnette A. Averill
Ketamine, a WHO essential medicine, has long been used globally as an anesthetic. Its off-label use for depression is growing, sparking discussions on efficacy, safety, and regulation.
Raquel Bennet, Sunny Strasburg, Gita Vaid, Danielle M Herrera, Lauren Taus
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.